预约演示

更新于：2025-01-23

Glioma of Brain, Familial

家族性脑胶质瘤

更新于：2025-01-23

基本信息

别名

GLIOMA OF BRAIN, FAMILIAL、GLM、Glioma of Brain, Familial

+ [1]

简介-

关联

项与家族性脑胶质瘤相关的药物

Trametinib dimethyl sulfoxide

二甲基亚砜曲美替尼

靶点

MEK1 x MEK2

作用机制

MEK1抑制剂 [+1]

在研机构

Novartis Pharmaceuticals Corp. [+12]

原研机构

GSK Plc

在研适应症

低级神经胶质瘤 [+109]

非在研适应症

肺腺癌 [+41]

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2013-05-29

TRI1215

靶点-

作用机制

免疫刺激剂

在研机构

北京启辰生生物科技有限公司

原研机构

北京启辰生生物科技有限公司

在研适应症

胶质瘤 [+1]

非在研适应症-

最高研发阶段临床1/2期

首次获批国家/地区-

首次获批日期1800-01-20

TRI 1022

靶点-

作用机制

免疫刺激剂

在研机构

北京启辰生生物科技有限公司

原研机构

北京启辰生生物科技有限公司

在研适应症

胶质瘤 [+1]

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期1800-01-20

项与家族性脑胶质瘤相关的临床试验

ChiCTR2300077403

/ RecruitingN/AIIT

Clinical study of Qingxiao method combined with small incision focus resection in the treatment of granulomatous lobular mastitis

开始日期2023-03-01

申办/合作机构-

ChiCTR2200058338

/ Recruiting临床4期IIT

Efficacy of ''Zhixiangpi and Baizhi Medicated Thread'' drainage in the treatment of granulomatous mastitis in abscess stage

开始日期2022-03-23

申办/合作机构-

NCT04201457

/ Recruiting临床1/2期IIT

Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine (HCQ) for BRAF V600E-mutant or Trametinib and HCQ for BRAF Fusion/Duplication Positive or NF1-associated Recurrent or Progressive Gliomas in Children and Young Adults

This phase I/II trial is designed to study the side effects, best dose and efficacy of adding hydroxychloroquine to dabrafenib and/or trametinib in children with low grade or high grade brain tumors previously treated with similar drugs that did not respond completely (progressive) or tumors that came back while receiving a similar agent (recurrent). Patients must also have specific genetic mutations including BRAF V600 mutations or BRAF fusion/duplication, with or without neurofibromatosis type 1. Neurofibromatosis type 1 is an inherited genetic condition that causes tumors to grow on nerve tissue. Hydroxychloroquine, works in different ways to stop the growth of tumor cells by killing the cells or stopping them from dividing. Trametinib and dabrafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving hydroxychloroquine with trametinib and/or dabrafenib may lower the chance of brain tumors growing or spreading compared to usual treatments.

开始日期2020-01-17

申办/合作机构

National Cancer Institute

100 项与家族性脑胶质瘤相关的临床结果

登录后查看更多信息

100 项与家族性脑胶质瘤相关的转化医学

登录后查看更多信息

0 项与家族性脑胶质瘤相关的专利（医药）

登录后查看更多信息

138

项与家族性脑胶质瘤相关的文献（医药）

2025-02-01·Annals of Surgical Oncology

The Value of Primary Tumor Resection in Patients with Liver Metastases: A 10-Year Outcome

Article

作者: Lin, Yu-Kun ; Xiang, Zuo-Lin ; Liu, Lin-Lin

AbstractObjectiveThis study aimed to analyze the impact of primary tumor resection (PTR) on the prognosis of four common primary tumors with liver metastases, and to develop a prognostic model to visualize the PTR benefit rate of patients with liver metastases.Materials and MethodsPatients diagnosed with colorectal cancer liver metastases (CRLM), pancreatic cancer liver metastases (PLM), gastric cancer liver metastases (GLM), and breast cancer liver metastases (BLM) between 2004 and 2015 were retrospectively reviewed from the Surveillance, Epidemiology, and End Results (SEER) database and assigned to either the surgery or non-surgery groups. A 1:1 propensity score matching (PSM) was performed. Surgical patients who survived longer than the median cancer-specific survival (CSS) time for non-surgery patients constituted the benefit group. Logistic regression was conducted to explore the independent factors affecting surgical benefit, and a nomogram was established.ResultsA total of 21,928 patients with liver metastases were included. After PSM for surgery and non-surgery patients, we found that PTR had a significant impact on the overall survival (OS) and CSS of CRLM, PLM, and BLM patients. In CRLM patients, age (p < 0.001), primary site (p = 0.006), grade (p = 0.009), N stage (p = 0.034), and histology (p = 0.006) affected the surgical benefit. In BLM patients, the independent factors were age (p = 0.002), race (p = 0.020), and radiotherapy (p = 0.043). And in PLM patients, chemotherapy was an independent factor associated with a survival benefit from PTR.ConclusionPTR improved OS and CSS in patients with CRLM, PLM, and BLM. A predictive model was established to identify suitable candidates for PTR in CRLM patients.

2025-01-13·Archives of Pathology & Laboratory Medicine

Infections Due to Corynebacterium kroppenstedtii With Focus on Granulomatous Lobular Mastitis for Tissue Specificity, Pathogenesis, Bacteriologic Workup, and Treatment

Article

作者: Shelburne, Samuel A. ; Zhang, Yu ; Ding, Qing Qing ; Ding, Yang ; Ehlers, Richard A. ; Gan, Qiong ; Lu, Huifang ; Han, Xiang Y. ; Wu, Yun ; Meng, Qing H.

Context.—Corynebacterium kroppenstedtiimay cause granulomatous lobular mastitis (GLM). Yet, current understanding is limited regarding its overall clinical significance, cultivation practice, GLM pathogenesis, and antimicrobial treatment.Objective.—To report the isolation and significance of C kroppenstedtii, features of patients with GLM, pathologic findings and mechanism, bacteriologic workup, and optimal treatment.Design.—Analysis of the cases with C kroppenstedtii at The University of Texas MD Anderson Cancer Center from 2016 to March 2024 for mechanistic insights.Results.—During a period of 8 years, isolates of C kroppenstedtii were obtained from 10 women and 7 men. All of the women, with an average age of 34 years (range, 18–61 years), presented with chronic or subacute mastitis, and were subsequently diagnosed with GLM. The men, with an average age of 66 years, had neoplastic diagnoses with the bacterium being commensal in 6 cases. Thus, C kroppenstedtii shows a predilection to infect the female breast (P < .001). Predisposing risks for GLM included childbirth in 8 women and nipple inversion in 2 women. Histopathology revealed xanthogranulomatous inflammation and Gram-positive bacilli within fat droplets or extracellularly. From GLM aspirates or tissue, the liquid culture media and/or anaerobic incubation yielded 9 of 10 isolates. Up to 14 tested strains were susceptible to vancomycin, linezolid, rifampin, and gentamicin. Nine women received extensive antimicrobial therapy.Conclusions.—Corynebacterium kroppenstedtiiis a rare commensal, is mammophilic, and causes GLM. Liquid culture media and/or anaerobic incubation offer the best culture recovery. The inflamed fatty milieu of the breast forms xanthogranulomas. Several antibiotics likely render effective treatment, particularly lipophilic rifampin, which penetrates the bacteria-laden fat droplets.

2024-10-01·Journal of Diabetes

Major adverse cardiovascular events’ reduction and their association with glucose‐lowering medications and glycemic control among patients with type 2 diabetes: A retrospective cohort study using electronic health records

Article

作者: Hwang, Wenke ; Kocis, Paul Thomas ; Hsu, Haowen ; Pichardo‐Lowden, Ariana

AbstractBackgroundCardiovascular diseases are a common cause of death among patients with type 2 diabetes (T2DM). Major adverse cardiovascular event (MACE) risks can be significantly reduced under adequate glycemic control (GC). This study aims to identify factors that influence MACE risk among patients with T2DM, including Hemoglobin A1c variability score (HVS) and early use of MACE‐preventive glucose‐lowering medications (GLMs).MethodsWe conducted a longitudinal cohort study to retrospectively review electronic health records between 2011 and 2022. Patients with T2DM ≥18 years without previous stroke or acute myocardial infarction (AMI) were included. Cox regression was utilized to investigate MACE risk factors and compare MACE risk reduction associated with early use of MACE‐preventive GLMs.ResultsA total of 19 685 subjects were included, with 5431 having MACE, including 4453 strokes, 977 AMI, and 1 death. There were 11 123 subjects with good baseline GC. Subjects with good baseline GC had 0.837 (confidence interval [CI]: 0.782–0.895) times lower MACE risk than their counterpart. Subjects with a single MACE‐preventive GLM at baseline with continuous use >365 days showed a decreased MACE hazard ratio (0.681; CI: 0.635–0.731). Among all MACE‐preventive GLMs, semaglutide provided a more significant MACE‐preventive effect.ConclusionsThis study identified that GLM, early GC, and HVS are MACE determinants among patients with T2DM. Novel GLM, adequate GC, and reduction of HVS can benefit MACE outcomes.

image

分析

对领域进行一次全面的分析。

或

查看完整样例数据

来和芽仔聊天吧

立即开始免费试用!

智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。

立即开始数据试用!

智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。